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Abstract
SNCA and MAPT genes and environmental factors are important risk factors of Parkinson’s disease [PD], the second-most
common neurodegenerative disease. The agrichemicals maneb and paraquat selectively target dopaminergic neurons,
leading to parkinsonism, through ill-defined mechanisms. In the current studies we have analyzed the ability of maneb and
paraquat, separately and together, to induce synucleinopathy and tauopathy in wild type mice. Maneb was ineffective in
increasing a-synuclein [a-Syn] or p-Tau levels. By contrast, paraquat treatment of mice resulted in robust accumulation of a-
Syn and hyperphosphorylation of Tau in striata, through activation of p-GSK-3b, a major Tau kinase. Co-treatment with
maneb did not enhance the effects of paraquat. Increased hyperacetylation of a-tubulin was observed in paraquat-treated
mice, suggesting cytoskeleton remodeling. Paraquat, but not maneb, inhibited soluble proteasomal activity on a peptide
substrate but this was not associated with a decreased expression of 26S proteasome subunits. Both paraquat and maneb
treatments increased levels of the autophagy inhibitor, mammalian target of rapamycin, mTOR, suggesting impaired axonal
autophagy, despite increases in certain autophagic proteins, such as beclin 1 and Agt12. Autophagic flux was also impaired,
as ratios of LC3 II to LC3 I were reduced in treated animals. Increased mTOR was also observed in postmortem human PD
striata, where there was a reduction in the LC3 II to LC3 I ratio. Heat shock proteins were either increased or unchanged
upon paraquat-treatment suggesting that chaperone-mediated autophagy is not hampered by the agrichemicals. These
studies provide novel insight into the mechanisms of action of these agrichemicals, which indicate that paraquat is much
more toxic than maneb, via its inhibitory effects on proteasomes and autophagy, which lead to accumulation of a-Syn and
p-Tau.
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Introduction
Parkinson’s disease [PD] is the second-most common neurode-
generative disease, after Alzheimer’s disease. Epidemiological
studies have linked agrichemicals to an increased risk of PD
through rural living, farming, drinking well water, and exposure to
agrichemicals used in these settings [1–3]. Several agrichemicals
can selectively damage dopaminergic neurons, leading to the
suggestion of an environmental basis for the development of
sporadic PD [4,5]. Indeed, experimental studies have shown
unique sensitivity of dopaminergic neurons to the herbicide
paraquat, with other populations of neurons unaffected [3,6],
along with reduced motor activity and dose-dependent losses of
striatal dopaminergic nerve fibers [7]. Additional evidence to
support paraquat’s status as a parkinsonism-inducing toxin comes
from data demonstrating up regulation and aggregation of a-
synuclein [a-Syn] within substantia nigra neurons in paraquat-
treated mice [8]. Maneb is a fungicide and permanent
parkinsonism has been reported following chronic occupational
exposure to maneb [9]. Some reports have suggested that the
toxicity of these agrichemicals is enhanced when used together,
and animals treated with paraquat and maneb together showed
synergistic reduction in motor activity and greater damage to both
striatal nerve terminals and nigral cell bodies, relative to treatment
with either agent alone [3,10–12]. Moreover, epidemiological
studies have also found increased risk for the development of PD
upon exposure to both paraquat and maneb [13].
At the molecular level, the mechanisms of action of paraquat
and maneb are not well understood. Paraquat inhibits complex I
of the mitochondria resulting in enhanced production of reactive
oxidative species, which in turn damages dopaminergic neurons
[14,15]. Additionally, paraquat reduces proteasomal function in
DJ-1 deficient mice, impairing clearance of dysfunctional proteins
[14]. Maneb causes oxidative stress through inhibition of complex
III and inhibits proteasomal activity in cultured cells [16],
although its effects on proteasomes in vivo are not known.
Several genome-wide studies have identified SNCA and MAPT,
the genes encoding a-Syn and Tau, respectively, as major risk
factors in the development of PD [17–20] and gene multiplications
of a-Syn are causal in the development of PD [21]. We have
demonstrated tauopathy in postmortem striata of PD patients, as
well as in in vitro and in vivo toxin and transgenic mouse models of
PD [22–27]. We found that Tau is abnormally hyperpho-
sphorylated in the striata at the following pathological epitopes:
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hyperphosphorylated Tau [p-Tau] were accompanied by increases
in aggregated a-Syn [27] and remodeling of the tubulin
cytoskeleton [26]. Central to the hyperphosphorylation of Tau
was the activation of GSK-3b (glycogen synthase kinase 3 b),
through its hyperphosphorylation at Tyr216 [24–27]. Both the
formation of p-Tau and activation of GSK-3b (p-GSK-3b), was
strictly dependent on the presence of a-Syn [22–24].
We undertook the current studies to analyze the chronic effects of
the agrichemicals, maneb and paraquat, on tauopathy and
autophagy in mice. Our results show that paraquat exposure results
in increased p-Tau levels in striata, enhanced a-Syn accumulation,
elevated p-GSK-3b levels and increased hyperacetylation of a-
tubulin. By contrast, maneb did not induce such changes nor did it
synergize the toxicity caused by paraquat alone; however, maneb
reduced paraquat-mediated increases in p-Tau. Paraquat, but not
maneb, caused inhibition of the proteasomal pathway, while both
maneb and paraquat caused alterations in key proteins of the
autophagy-lysosomal pathway [A-LP], with maneb enhancing some
effects of paraquat. Neither agrichemical caused alterations in
markers of chaperone mediated autophagy [CMA]. These studies
provideforthefirsttimeunique insight into the mechanisticprocesses
that occur in vivo in the striata upon exposure to agrichemicals.
Results
Toxicity of maneb and paraquat in mice
Neither maneb nor paraquat alone caused mortality of mice in
this study. However, when combined together, maneb+paraquat
showed high levels of toxicity with a mortality rate of 40%. Such
high levels of mortality in the combined treatments were also
found earlier, where 42% of animal death was reported [28].
Effect of maneb and paraquat on synucleins, p-GSK-3b
and GSK-3b in striata
Previous studies have shown that maneb and paraquat induced
parkinsonian behavior in mice and that maneb synergistically
enhanced the effects of paraquat when both these agents were used
together [10–12], but the biochemical mechanisms underlying
such induction has not been previously reported. To study the
effects of these agrichemicals, mice were chronically injected twice
a week for 6 weeks with maneb or paraquat alone, or with
maneb+paraquat, as described under Methods. Striata were
isolated, lysed in sodium cholate, and both cholate-soluble and
cholate-insoluble fractions were used for analyses. Since there were
no significant changes in any of the proteins in the cholate-
insoluble fractions, only the data from the cholate-soluble fractions
are presented below in Figure 1.
Treatment of mice with maneb failed to cause any significant
increases [24%, p.0.05] in the expression levels of a-Syn [Mr
17 kDa] in cholate-soluble fractions, compared to control saline-
treated mice [Fig. 1A]. By contrast, paraquat caused a significant
[p,0.01] increase [of 133%] in the levels of a-Syn in the striata,
compared to control saline-treated mice. In mice injected with
maneb+paraquat, significant [p,0.01] increases [121%] in a-Syn
levels were also observed compared to control mice. Since this
increase was not significantly different than that obtained using
paraquat alone, this suggests that maneb did not enhance the
toxicity of paraquat in the induction of synucleinopathy.
Figure 1. Effect of maneb and paraquat on synucleins, p-GSK-3b and GSK-3b in striata. Striata from saline, maneb, paraquat, and
maneb+paraquat injected mice were dissected and homogenized in a modified RIPA buffer containing 1.0% sodium cholate. Cholate-soluble
fractions were isolated by centrifugation and analyzed by Western blots, as described under ‘‘Materials and Methods’’. After exposure to antibodies,
blots were stripped and re-probed for other proteins. The blots show representative gels while the bar graphs are composites of blots summarized
from all animals (n=5–6). (A) a-Syn and b-Syn were expressed relative to b-actin used as a loading control. (B) p-GSK-3b levels were probed using
antibodies which recognizes a phosphorylation site at Tyr216; both p-GSK-3b and total GSK-3b were expressed relative to b-actin used as a loading
control. Values are mean 6 SEM as compared to saline-injected animals. Asterisks (**) indicate values significantly different from saline controls
(p,0.01). Student’s t-test was performed to compare saline-treated controls and treatment groups for all data.
doi:10.1371/journal.pone.0030745.g001
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16,kDa] in cholate-soluble fractions [Fig. 1A]; b-Syn antagonizes
the effects of a-Syn and exerts a protective effect on neurons, by
counteracting a-Syn toxicity [29]. Neither maneb nor paraquat
alone showed significant changes in b-Syn levels (22% increase
and 2% decrease compared to control saline-treated mice,
respectively, p.0.05). When combined, however, maneb+para-
quat significantly decreased b-Syn expression levels (by 28%,
p,0.05).
We next measured changes in p-GSK-3b, a major kinase known
to phosphorylate Tau, whose autophosphorylation at Tyr216
causes activation of the kinase [Fig. 1B]. The antibody against p-
GSK-3b also recognizes p-GSK-3a, detectable as a band of
Mr,52 kDa visible above p-GSK-3b; in our studies, only the
lower band, corresponding to p-GSK-3b [Mr of 46 kDa], was used
to calculate for levels of this protein. In maneb-treated mice,
increases [7% compared to control saline-treated mice, p.0.05] in
p-GSK-3b levels were not observed in striata. In paraquat-treated
mice, however, we saw elevated levels [of 36%] in p-GSK-3b that
were highly significant [p,0.01, Fig. 1B]. Similarly, in mice
treated with maneb+paraquat, we also saw higher levels of p-
GSK-3b [30%] which were significantly [p,0.01] different from
control mice; maneb treatments did not synergize the activation of
p-GSK-3b seen by paraquat alone.
High levels of total non-phosphorylated GSK-3b were also
seen in paraquat and maneb+paraquat treated animals [Fig. 1B].
Thus, in maneb-treated mice, total GSK-3b levels were
unchanged [22% increase compared to control, saline-treated
mice, p.0.05]. In paraquat-treated mice, total GSK-3b levels
were increased by 64% [p,0.01], whereas in maneb+paraquat
animals the increase was 55% [p,0.01]. These increases in total
GSK-3b are likely to be a result of the chronic treatments over a
6 week period, such that increases in total GSK-3b offset the
observed increases in p-GSK-3b. That maneb failed to enhance
p-GSK-3b or total GSK-3b levels when used alone, or when used
in combination with paraquat, further indicates lack of toxicity of
maneb in mice striata and lack of synergy between the two
compounds, respectively.
Effect of maneb and paraquat on expression levels of
hyperphosphorylated Tau in striata
Tau is a microtubule-stabilizing protein located within axons in
neurons, whose hyperphosphorylationat certainsites is known to be
pathological, leading to dissociation of Tau from microtubules,
microtubule destabilization, loss of axonal transport and neuronal
degeneration [30–33]. We examined p-Tau hyperphosphorylated
at Ser202 [observed as a doublet with Mr of 50 and 56 kDa], and
found no significant changes [14% increase, p.0.05] in striata of
maneb-treated mice [Fig. 2]. By contrast, in paraquat-treated mice,
a significant [p,0.01] increase [of 67%] in pSer202 Tau was
observed, which remained significantly [p,0.05] elevated in
maneb+paraquat-treated mice [increase of 38%]. pSer262 levels,
detected as a smeary series of bands with Mr of 50–60 kDa, were
unchanged in maneb-treated mice when compared to saline-treated
control mice [Fig. 2], while in paraquat-treated mice a significant
increase [67% increase, p,0.01] was seen. In maneb+paraquat-
treated mice, levels of pSer262 remained elevated [28%, p,0.05].
pSer396/404 Tau levels [Fig. 2], probed by the PHF-1 antibody
and detected as a single band with Mr of 50 kDa, were increased in
maneb-treated mice [23%] but the increase was not significant
[p.0.05].Inparaquat-treatedmicevery high levelsofpSer396/404
were seen [240% increase, p,0.01], and remained high in
maneb+paraquat mice [141%, p,0.01].
We also examined total Tau levels, detected as a single band
with Mr of ,55 kDa [Fig. 2], and found Tau levels to be
increased in maneb-treated mice [23%], but the increase was
not significant [p.0.05]. In paraquat-treated mice, total Tau
was increased [81%], while in maneb+paraquat-treated mice,
Tau increased by 90%, and both increases were highly
significant [p,0.01]. It should be noted that when either cells
[22–24] or mice [unpublished observations] are acutely treated
with toxins, this does not lead to changes in total Tau levels,
due to lack of long-term effects on microtubules. However, in
the current studies, when mice were chronically treated with
toxins which affects microtubule stability [see below], this leads
to an overall increase in total Tau, likely due a feed-back
mechanism causing an increase in synthesis of total Tau to
compensate for stabilization of microtubules. The pattern of
increases in p-Tau and total Tau levels in these mice indicates
that whereas paraquat treatments significantly increases tauo-
pathy in striata of mice, maneb treatments do not, nor does
maneb augment the tauopathy caused by paraquat alone.
These findings further support our contention that when
microtubules are destabilized under chronic conditions of
treatments, total Tau increases in a compensatory manner,
similar to the increase in total GSK-3b s e e na b o v ei nF i g u r e1 B ,
to offset a long-term sustained increase in p-GSK-3b,w h i c h
eventually leads to microtubule stability.
Figure 2. Effect of maneb and paraquat on expression levels of hyperphosphorylated Tau in striata. The blots show representative gels
while the bar graphs are composites of blots summarized from all animals (n=5–6). p-Tau and Total Tau were probed using antibodies specific for
pSer202, pSer262, pSer396/404, and Tau-5, respectively, and expressed relative to b-actin used as loading control. Values are mean 6 SEM as
compared to saline injected control. Asterisks (*, **) indicate values significantly different from saline controls (p,0.05, p,0.01, respectively).
Student’s t-test was performed to compare control and treatment groups for all data.
doi:10.1371/journal.pone.0030745.g002
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Earlier studies have shown that an excess of Tau protein
increases hyperacetylation of a-tubulin, through an inhibitory
effect on histone deactylase 6, whose substrates include tubulin
[34]. While a-tubulin acetylation enhances microtubule stability,
excessive acetylation can impair retrograde axonal transport [35].
We decided to investigate whether the increased levels of Tau and
p-Tau seen in striata of paraquat treated mice results in changes in
the state of a-tubulin acetylation. Striata from mice were extracted
in PIPES buffer and centrifuged to isolate cytoskeleton-free
(PIPES) and cytoskeleton-associated (SDS) fractions, as described
in Methods, and levels of acetylated a-tubulin were examined in
both fractions. Under normal conditions, a-tubulin levels are low
in cytoskeleton-free fractions; however, when microtubules are
destabilized, elevated levels of free a-tubulin appear in cytoskel-
eton-free fractions. While there were no changes in total a-tubulin
present in the cytoskeleton-free fraction, large increases in
acetylated free a-tubulin [of 185%, p,0.05] were seen in
paraquat-treated mice, with smaller increases [,40%, p,0.05]
in mice treated with both maneb and paraquat [Fig. 3A]. Such
increases in free a-tubulin represent destabilization of a-tubulin.
Maneb alone failed to induce any changes in acetylated a-tubulin
in the cytoskeleton-free fractions, suggesting that this toxin did not
cause destabilization of microtubules. The increases in acetylated
a-tubulin in cytoskeleton-free fractions were accompanied by a
corresponding decrease in acetylated a-tubulin in cytoskeleton-
associated fractions of paraquat-treated and maneb+paraquat-
treated mice [40 and 44%, respectively, p,0.01, Fig. 3B].
Interestingly, total a-tubulin levels were also decreased in
maneb+paraquat-treated mice [35%, p,0.01] [Fig. 3B].
Effect of maneb and paraquat on proteasomal activity
The primary pathway by which proteins are cleared from cells is
through proteasomes, and the increased accumulation of a-Syn
and p-Tau suggested to us that proteasomal activity may be
impaired by the agrichemicals. Studies have shown that paraquat
reduces proteasomal activity by 30% in wild type and DJ-1
deficient mice [14]. Maneb was also found to inhibit proteasomal
Figure 3. Effect of maneb and paraquat on acetylation of tubulin. Using the PIPES method to extract cytoskeleton-free fractions (A, PIPES) by
centrifugation, pellet fractions were solubilized in SDS to re-suspend cytoskeleton-associated fraction (B, SDS). Both cytoskeleton-free and
cytoskeleton-associated fractions were analyzed by Western blots. The blots show representative gels while the bar graphs are composites
summarized from all animals (n=5–6). Acetylated-a-tubulin was probed using antibodies specific for acetylated a-tubulin and expressed relative to b-
actin used as loading control. Values are mean 6 SEM as compared to saline injected control. Asterisks (*, **) indicate values significantly different
from saline controls (p,0.05, p,0.01, respectively). Student’s t-test was performed to compare control and treatment groups for all data.
doi:10.1371/journal.pone.0030745.g003
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cells and its effect on proteasomes in vivo is not known. For these
reasons, we decided to examine proteasomal activity in striata of
these mice [Fig. 4A]. Lactacystin-sensitive digestion of the model
substrate suc-LLVYAMC was used to measure activity of the 20S
proteolytic component of the 26S proteasome. Cleavage of LLVY
is independent of ubiquitylation or 19S chaperone activity and so
is considered a direct measure of 26S proteolytic activity. Pre-
liminary experiments demonstrated that greater than 80% of the
total 26S proteolytic activity was extracted into soluble fractions by
our extraction procedure.
In maneb-treated mice, 26S proteolytic activity was not
significantly different [95% of control, p.0.05%] than that obtained
in saline-treated mice [Fig. 4B]. In paraquat-treated mice, 26S
proteolytic activity was significantly reduced [by 40%, p,0.05]
comparedtocontrolsaline-treated mice.The26Sproteolyticactivity
in maneb+paraquat-treated mice was also significantly [p,0.05]
reduced [by 35%] compared to control mice and was comparable
with the activity seen in mice treated with paraquat alone.
In order to ascertain whether the reduction in 26S proteolytic
activity was due to alterations in the subunits of the proteasome,
we examined the protein levels of representative subunits of both
the 19S and 20S components (S69 and alpha 5, respectively) of the
26S proteasome by Western blots [Fig. 4B]. While we consistently
observed alterations in total proteasome levels in certain groups,
these did not correlate with reductions in 26S proteolytic activity
and measured by LLVY cleavage. Both the 19S and 20S subunits
were detected at similarly reduced levels in maneb treated mice
(38% and 32%, respectively) relative to control samples. The
similar reduction in both the 19S and 20S subunits suggests that
there were no substantial alterations in 26S assembly. While this
reduction was statistically significant [p,0.05], it was not
associated with a decease in proteolytic activity. In paraquat-
treated mice, 19S S69 levels were increased by 13%, while in
maneb+paraquat-treated animals, an increase of 20% was
observed. Levels of the 20S alpha 5 subunit in paraquat and
maneb+paraquat-treated mice were decreased by 5 and 13%,
respectively. However, none of the changes in proteasomal
expression levels associated with paraquat or paraquat+maneb
treated mice were statistically significant [p.0.05]. These data
indicate that decreases in proteasomal proteolytic activity observed
upon treatment with paraquat were not due to loss of either the
Figure 4. Effect of maneb and paraquat on proteasomal activity. (A) Prior to setting up the assay protocol, brain samples were extracted by
sodium cholate, and sample assays from both insoluble and soluble fractions ranged from 579–3845 units and 31,000–78,000 units, respectively,
indicating that the solubilization protocol was working optimally. Aliquots from soluble extracts were used to measure 26S proteasomal activity as
described under ‘‘Materials and Methods’’. Lactacystin-sensitive digestion of the model substrate suc-LLVYAMC was used to measure 26S proteasome
activity, expressed via AMC fluorescence. (B) Samples were further homogenized in a modified RIPA buffer containing 1.0% sodium cholate, and
analyzed by Western blots. After exposure to initial antibodies, blots were stripped and probed for other proteins. The blots show representative gels
while the bar graphs are composites summarized from all animals (n=5–6). Proteasomal proteins 19S and 20S were probed using antibodies specific
for the 19S 6S9 subunit and 20S a5 subunit, and expressed relative to b-actin used as loading control. Values are mean 6 SEM as compared to saline
injected control. Asterisks (*, **) indicate values significantly different from saline controls (p,0.05, p,0.01, respectively). Student’s t-test was
performed to compare control and treatment groups for all data.
doi:10.1371/journal.pone.0030745.g004
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proteasome. Instead, paraquat appears to have a direct inhibitory
effect on the proteolytic activity of the 20S component of the
proteasome.
Additionally, since both a-Syn and p-Tau bind to proteasomes
reducing its activity [25,40], the decreases in proteasomal activity
upon paraquat or paraquat+maneb treatment, may at least be due
in part to the direct inhibitory effects of a-Syn and p-Tau, which
are produced by paraquat. Moreover, since maneb treatments do
not induce increases in a-Syn and p-Tau, the lack of changes in
proteasomal activity in maneb-treated fractions may be explained
by the absence of a-Syn and p-Tau.
Effect of maneb and paraquat on axonal autophagy and
chaperone-mediated autophagy
When proteasomes are inhibited, misfolded proteins such as a-
Syn and p-Tau start to aggregate and accumulate at nerve
terminals. This in turn triggers the activation of both chaperone
mediated autophagy [CMA] and the autophagic lysosomal
pathway [A-LP]. Proteins are then conjugated to individual heat
shock proteins or packaged into autophagosomes, where they are
transported back to cell soma containing lysosomes and Lamp2a,
through retrograde transport by dynein along MTs [36–39,41].
Since the effect of these agrichemicals on axonal autophagy is not
known, we decided to examine the major components of axonal
autophagy in striatal lysates.
In cholate-soluble fractions, both maneb and paraquat signif-
icantly [p,0.01] increased [35 and 43%, respectively] levels of the
mammalian target of rapamycin [mTOR], an overall inhibitor of
A-LP; when used together, maneb+paraquat augmented the
increase in mTOR levels [81%, p,0.01] [Fig. 5A]. Elevated
levels of mTOR were also detected in cholate insoluble fractions
treated with paraquat alone [Fig. 5B, 103%, p,0.05] or
maneb+paraquat [Fig. 5B, 245%, p,0.01]. Significant [p,0.01]
increases in levels of beclin 1, an inducer of autophagy, were also
seen in cholate-soluble fractions under all three treatment
paradigms, with increases ranging from 81–95% [Fig. 5A]. In
cholate-insoluble fractions, however, no significant changes in
beclin 1 levels were observed, and in fact small decreases were seen
[Fig. 5B]. Levels of Atg12, another inducer of A-LP, were also
increased in cholate-soluble extracts of paraquat and paraquat+-
maneb-treated striata [36 and 62%, respectively, p,0.01], but not
in maneb-treated animals [Fig. 5A]. In cholate insoluble fractions
[Fig. 5B], significant increases in Atg12 levels were noted only for
paraquat+maneb treatments [45%, p,0.05]. In the A-LP
pathway, a single inhibitor of this pathway exists, mTOR, while
numerous activators of the pathway, beclin 1, Atg5, Atg7 and
many other Atg proteins are also found. Our data suggests that
despite increases in beclin 1 and Atg12, the sharp increases in
mTOR may override the stimulatory effects of these other
proteins, leading to an overall mTOR-mediated inhibition of A-
LP in this system.
To gain further understanding of whether autophagosomes are
formed, which would enable us to determine whether A-LP is
inhibited, we examined levels of the microtubule-associated
protein 1 light chain 3 [LC3], which is an essential component
of the autophagosome [Fig. 5C]. In particular, newly synthesized
LC3 is proteolytically cleaved to a smaller protein [LC3 I,
Mr,16 kDa] which becomes lipidated [LC3 II, Mr,14 kDa] and
is then inserted into the autophagosome.
Ratios of lipidated LC3–II to cytosolic LC3-I provide an
important indicator for monitoring the autophagic activity (or flux)
[38]. We therefore measured the LC3 II to LC3 I ratio in cholate
soluble fractions using the LC3B antibodies [Fig. 5C]. It should be
noted that LC3 II bands are not very stable and when present, are
often present as small punctate proteins or faint bands. From
Figure 5C, only low and faint levels of LC3 II bands were visible,
below the stronger, darker LC3 I bands. When ratios were
calculated, the ratio was significantly depressed in all treatment
groups [maneb, 42%, p,0.001; paraquat, 24%, p,0.05;
maneb+paraquat, 23%, p,0.05], indicative of a lowered level of
autophagic flux compared to the saline-treated group (Fig. 5C).
We next examined components of chaperone-mediated au-
tophagy. Levels of the heat-shock cognate protein 70 [Hsc70] were
only modestly increased in cholate-soluble fractions [Fig. 5D] from
maneb and maneb+paraquat treated mice [8–19%, p,0.05],
while in the cholate-insoluble fractions [Fig. 5E], this protein was
greatly increased [by 85%, p,0.01] in the paraquat+maneb
treated mice. Heat-shock protein 70 [Hsp70] levels were reduced
in cholate-soluble extracts from maneb treated mice, while a small
but significant [p,0.01] increase of 21% was seen in paraquat+-
maneb treated animals [Fig. 5D]. No significant changes were seen
in Hsp70 levels in cholate-insoluble fractions [Fig. 5E]. When
Hsp90 levels were examined [Fig. 5D], significant [p,0.01]
increases were seen in soluble fractions from maneb [35%],
paraquat [43%] and maneb+paraquat [81%] treated mice.
Increased levels of Hsp90 were also seen in insoluble fractions
for maneb and maneb+paraquat treatments [39% and 55%,
respectively, p,0.05, Fig. 5E]. Together, these data suggest that
levels of the heat shock proteins are increased after maneb and
paraquat treatments.
Immunohistochemical co-localization in Striatum and
Midbrain
To further explore the relationship between a-Syn, p-Tau and
autophagy, dual immunohistochemical [IHC] staining was
conducted, and co-localization of a-Syn with mTOR or PHF-1
Tau (p-Tau) was evaluated in striatal and midbrain sections of
paraquat-treated or control mice [Fig. 6]. In both striata [Fig. 6A]
and midbrain sections [Fig. 6C] increased immunostaining, with
co-localization, was seen for a-Syn and p-Tau in paraquat-treated
mice compared to saline-treated mice. Dual staining of a-Syn and
mTOR in striatal [Fig. 6B] and midbrain sections [Fig. 6D]
showed elevated levels of both proteins that were co-localized with
one another in the paraquat-treated versus saline-treated mice.
These results are consistent with the Western blot analysis of
Fig. 5A, showing increased levels of mTOR. mTOR showed a
more punctate staining pattern in the striatal samples, whereas in
the midbrain, the staining was more diffuse. It is interesting to note
that some mTOR staining was observed in the saline-treated mice
for both striatal and midbrain regions, with a peri-nuclear
localization. This is in contrast to the paraquat-treated sections
in which a-Syn and mTOR is seen being distributed more in the
cytoplasmic cell body.
Impaired axonal autophagy in postmortem striata of
Parkinson’s disease
No studies have been conducted on axonal autophagy in nerve
terminals in PD. To assess if axonal autophagy is impaired in PD,
we examined mTOR and major proteins involved in autophago-
some formation in postmortem striata from PD patients and age-
matched non-diseased controls [N=10–17 each]. Striata were
solubilized in 1% sodium cholate and cholate-soluble and cholate-
insoluble fractions were isolated and examined by Western blots
[Fig. 7A]. In cholate-soluble supernatant fractions, there was a
significant increase [63%, p,0.01] in mTOR levels in PD striata
compared to controls, while in cholate-insoluble fractions, mTOR
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30745Figure 5. Effect of maneb and paraquat on autophagic pathway. Striata from saline, maneb, paraquat, and maneb+paraquat injected mice
were homogenized in a modified RIPA buffer containing 1.0% sodium cholate, and separated into cholate-soluble and cholate-insoluble fractions and
analyzed by Western blots, as described under ‘‘Materials and Methods’’. The blots show representative gels while the bar graphs are composites
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also observed decreases of ,35% [p,0.01] in Atg12 levels. There
were no significant changes in levels of beclin 1 or Atg7 in PD
brains compared to controls. There were also no changes in levels
of markers of chaperone-mediated autophagy, Hsc70, Hsp70 and
Hsp90.
In striatal cholate-insoluble fractions [Fig. 7A], Atg7 levels were
significantly reduced [by 40%, p,0.01], whereas Atg12 levels were
increased [50%, p,0.01] in PD. Interestingly, Hsc70 levels were
decreased [50%, p,0.01] in pellet fractions, while Hsp70 and
Hsp90 levels were unchanged.
We also calculated the LC3 II to LC3 I ratios in human PD
striatum [Fig. 7B] and found that this ratio was significantly
reduced [40%, p,0.001] in PD brain compared to controls,
indicating reduced autophagic flux.
Together, the combined data suggest an overall inhibition of
axonal autophagy via increased levels of mTOR, along with an
impaired ability to form autophagosomes and reduced chaperone-
mediated autophagy by Hsc70.
Discussion
The data presented here shows for the first time that paraquat
induces a broad spectrum of pathological changes in striata which
includes synucleinopathy, tauopathy, destabilization and hyper-
acetylation of microtubules, and inhibition of both proteasomal
and autophagic pathways. By contrast, the effects of maneb were
much milder, causing only a modest inhibition of A-LP and a
decrease in autophagic flux. Moreover, apart from increasing
mTOR levels, maneb also did not appear to enhance the
pathology of paraquat, which is in contrast to previous reports
suggesting that maneb synergizes paraquat-mediated toxicity
[10,11]. Yet, maneb and paraquat together was much more toxic
to animals than either agrichemical used alone, resulting in ,40%
mortality of animals. Together, these data imply that paraquat is
much more toxic than maneb, inducing changes in striata which
mimic those seen in sporadic PD [25], which include synucleino-
pathy, tauopathy, microtubule destabilization, inhibition of
proteasomes and A-LP.
The tauopathic changes in striata of mice induced by paraquat,
indexed by elevated levels of pSer202, pSer262 and pSer396/404,
are the same sites that we have previously shown to be
hyperphosphorylated in PD postmortem striata [25]. It is now
well-established that hyperphosphorylation of Tau at such
pathological epitopes can initiate the neurodegenerative process,
since hyperphosphorylation reduces the ability of Tau to bind to
microtubules, leading to enhanced destabilization of the microtu-
bular network, disruption of axonal transport, with eventual
degeneration of nerve terminals [30–32]. In particular, hyperpho-
sphorylation at Ser262 detaches Tau from MTs [33] and
hyperphosphorylation at Ser396/404 promotes self assembly of
Tau to form aggregates [30–32]. In mice striata, paraquat
treatment caused increased levels of soluble total Tau to be
present in cholate-soluble extracts, along with increased levels of
hyperacetylated a-tubulin in cytoskeleton-free fractions and
reduced levels of hyperacetylated a-tubulin in cytoskeleton-
associated fractions, suggesting remodeling of the microtubule
cytoskeleton.
Paraquat also caused increases in a-Syn levels in striata of mice,
but the additional presence of maneb did not augment this
increase. Moreover, paraquat-treatment led to increased activity of
p-GSK-3b, hyperphosphorylated at Tyr216. p-GSK-3b is a major
kinase involved in the hyperphosphorylation of Tau at numerous
sites, and its activation and role in mediating Tau hyperpho-
sphorylation in PD has now been established through studies we
have conducted in postmortem PD striata [25] and in in vitro and in
vivo models of PD [24,27]. Interestingly, treatment of mice with
both MPTP [22] and paraquat [the current study] leads to similar
changes in a-Syn, p-GSK-3b and p-Tau, and this may be due to a
high degree of overlap in the structural homology and mechanism
of action shared by these chemicals. In contrast to paraquat,
maneb failed to cause increases in levels of a-Syn or to activate
GSK-3b, nor did maneb augment paraquat-induced increases in
these proteins. Moreover, the effect of maneb on paraquat with
regard to p-Tau formation suggests that maneb may act to reduce
paraquat-mediated tauopathy. Thus, maneb significantly reduced
levels of both pSer262 and pSer396/404 in mice co-treated with
paraquat. Although this did not change the overall levels of soluble
total Tau, the additional presence of maneb diminished the levels
of cytoskeleton-free acetylated a-tubulin.
Furthermore, unlike paraquat, maneb did not directly inhibit
26S proteolytic activity in vivo, nor did it exacerbate the direct
inhibitory effect of paraquat on this activity. Maneb treatment
resulted in a moderate but significant decrease in 26S steady state
expression levels, as measured by representative components from
the 19S and 20S subunits, which was alleviated by co-treatment
with paraquat. However, this reduction was not accompanied by a
reduction in ubiquitin-independent 26S proteolytic activity on a
peptide substrate, indicating that the level of proteolytically active
proteasomes was not directly related the total proteasome levels in
these samples. Control of 26S proteasome expression is complex,
and our data suggest that maneb has a direct or indirect effect on
this process. Small increases in proteasomal components seen in
paraquat treated samples may be the result of compensatory
changes in response to proteolytic inhibition and may account for
the alleviation of the effect of maneb on expression. We can not
rule out the possibility that decreases in steady state levels of 26S
proteasome in maneb-treated mice could lead to decreased
efficiency of degradation of specific ubiquitylated substrates, which
may partially account for the extreme toxicity seen in doubly-
treated mice. Toxicity would arise from a direct effect of paraquat
on proteolytic activity, something that would affect all substrates,
and an effect of maneb on 26S expression level, which may affect
some substrates more than others. This will be an important area
of future study. Whatever the mechanism, proteasomal inhibition
is known to be toxic to cells, as it prevents cells from processing
proteins targeted for degradation. Decreases in proteasomal
activity have been previously noted in PD substantia nigra [41]
and PD striata [25] which may partially account for accumulation
of both a-Syn and p-Tau seen in dopaminergic neurons, which
then interact with one another leading to formation of Lewy
bodies and Lewy neurites.
summarized from all animals (n=5–6). (A) Autophagy pathway proteins in the soluble and (B) insoluble supernatant were probed using antibodies
specific for mTOR, Beclin1, and Atg12, and expressed relative to b-actin used as loading control. (C) LC3 I (upper band) and LC3 II (lower band in
longer exposure blot image) were probed in cholate soluble fractions using LCB antibodies, and the ratio of LC3 II to LC3 I was assessed to measure
autophagic flux. (D) Chaperone proteins in the cholate soluble and (E) cholate insoluble fractions were probed using antibodies specific for Hsc70,
Hsp70, and Hsp90, and expressed relative to b-actin used as loading control. Values are mean 6 SEM as compared to saline injected control. Asterisks
(*, **, ***) indicate values significantly different from saline controls (p,0.05, p,0.01, p,0.001,respectively). Student’s t-test was performed to
compare control and treatment groups for all data.
doi:10.1371/journal.pone.0030745.g005
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with regard to their effects on autophagy. In neurons, when
proteasomes are inhibited, the A-LP is activated as a means of
degrading proteins originally targeted to the proteasome [37]. Both
Figure 6. Immunohistochemical co-localization in striatum and
midbrain. Representative striatum (A–B) and midbrain (C–D) sections
double immunostained for a-Syn (Red), with PHF-1 Tau (Green), or
mTOR (Green) and nuclei with DAPI (Blue). Single antibody images from
saline (Sal, top panel) and paraquat (PQ, bottom panel) treated mice
shown at 406. White boxes indicate highlighted areas shown at greater
magnification in side panels, far right. (A) Striatum immunostained with
a-Syn (Red), PHF-1 Tau (Green), and DAPI (Blue). (B)S t r i a t u m
immunostained with a-Syn (Red), mTOR (Green), and DAPI (Blue). (C)
Midbrain immunostained with a-Syn (Red), PHF-1 Tau (Green), and DAPI
(Blue). (D) Midbrain immunostained with a-Syn (Red), mTOR (Green),
and DAPI (Blue). Scale bar 10 mm.
doi:10.1371/journal.pone.0030745.g006
Figure 7. Western blot analyses of striata from PD brains and
age-matched controls. (A) Cholate soluble and cholate insoluble
fraction from PD striata and age-matched controls were analyzed by
Western blots. Blots show representative gels while bar graphs are
composites summarized from all postmortem tissues (n=10–17). All
proteins were expressed relative to b-actin used as loading controls. (B)
LC3 II/LC3 I ratios were calculated to assess autophagic flux. Values are
mean 6 SEM as compared to age-matched control tissue. Asterisks
(*, **) indicate values significantly different from controls (p,0.05,
p,0.01, respectively). Student’s t-test was performed to compare
control and PD samples for all data.
doi:10.1371/journal.pone.0030745.g007
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autophagy [36–39], suggesting that the A-LP is dysfunctional in
these mice. Interestingly, maneb augmented the increase in mTOR
levels elicited by paraquat alone, suggesting that maneb+paraquat
produces the greatest inhibition of ALP than either of the
agrichemicals used alone. The high levels of mTOR may lead to
compensatory increases in levels of other components of the A-LP,
such as beclin 1, a major initiator of autophagy [36–39], as well as
Atg12, a marker of the early stages of A-LP and a protein important
in autophagosome formation. It is noteworthy that we found
reduced autophagic flux upon agrichemical treatment and these
findings areatodds with thoseofothers[42],who foundincreasesin
LC3 proteins associated with autophagic vacuoles in cultured SH-
SY5Y cells treated with paraquat. This may be due to differences
thatareintrinsictoinvitroversusinvivomodels,or,alternatively,may
be due to differences in the effect of acute treatments [42] and
chronic treatments [our study] on LC3 function. Our IHC findings
in midbrain regions indicate that impaired autophagy, as indexed
by increased levels of mTOR in these regions, is not restricted to
striata, but is also evident in cell soma.
CMA is an important pathway by which aggregates of proteins
are cleared from nerve terminals [36–39]. In this pathway,
proteins at nerve terminals destined for degradation bind to heat-
shock chaperone proteins, such Hsc70, Hsp70 and Hsp90
proteins, and are then delivered to lysosomes in the cell soma
through retrograde transport on microtubules [43,44]. With the
exception of maneb, in paraquat and paraquat+maneb treated
mice, the levels of the three heat shock proteins measured, Hsc70,
Hsp70 and Hsp90, either increased or were unchanged compared
to control mice; in maneb-treated mice, Hsp70 levels were
modestly reduced, while both Hsc70 and Hsp90 levels were
increased. This suggests that the CMA pathway in these mice is
not likely to be impaired, and may function normally. Indeed,
CMA up regulation and increases in Hsp70 have been previously
observed in mice after a single injection of paraquat [45].
However, in our studies, it is not clear whether chaperone proteins
with their cargoes reach the cell soma, since such retrograde
transport of CMA is dependent on microtubules, and the high
levels of acetylated a-tubulin seen after PQ treatments may
hamper appropriate delivery of these cargoes to the lysosome in
the cell soma. Indeed, hyperacetylation of a-tubulin has been
previously shown to lead to impaired microtubular transport of
mitochondria [35], and the hyperactylated a-tubulin observed
after paraquat treatment may similarly hamper CMA. This,
together with impaired proteasomal activity and A-LP, may be the
major reasons leading to accumulation of a-Syn and p-Tau in
paraquat-treated striata.
Our findings in paraquat-treated mice parallel those seen in PD
postmortem striata, where we observed high levels of mTOR,
suggesting impairment of ALP in nerve terminals. Moreover, we
also observed decrease in the LC3 II to LC3 ratio in cholate-
soluble extracts of PD striata. Unlike our findings in paraquat-
treated mice, PD striata demonstrated reductions in Atg7 and
Atg12 proteins, further indicating that ALP may be impaired in
PD compared to age-matched non-diseased controls. Although
neither Hsp70 nor Hsp90 levels were changed in PD striata
compared to age-matched controls, Hsc70 levels were substantially
reduced in cholate-insoluble fractions. This suggests that CMA
may be impaired in PD.
This is one of the first studies showing impairments in
autophhagic pathways in PD. Previously, a study found dimin-
ished Hsc 70 levels in Substantia nigra in PD post mortem tissues
[46] while another study found decreases in Lamp-2 gene
expression in the peripheral leukocytes of patients with sporadic
Parkinson’s disease [47]. As further research is conducted, the
precise impairment and role that autophagy plays in PD will
become evident, but it is clear.
There are only a small number of studies that have examined
the effects of environmental toxins on tauopathy, even though
tauopathy is a key feature common to most neurodegenerative
diseases. Previously, rotenone was shown to cause widespread
tauopathy in rat brain [48] and in cultured neurons of
hippocampus, substantia nigra and locus coeruleus [49]. In both
studies, increases in a-Syn levels were also found. Such studies,
including our current one, clearly document the ability of
agrichemicals to cause tauopathy that leads to neurodegeneration,
resembling that seen in diseases of unknown etiology such as PD
and AD. Paraquat remains one of the most widely used herbicides
in the world and in an ever aging population its continued use may
prove to be especially harmful, leading to a higher incidence of
such diseases.
Materials and Methods
Materials
The antibodies used in this study are: anti-Tau MAB361 from
Millipore [Temecula, CA]; anti-Tau Neurofibrillary Tangles
Marker (Tau-5) AHB0042, anti-tau (pS262), and anti-Tau
(pS396; immunohistochemistry only) from Biosource Invitrogen
[Carlsbad, CA]; anti-a-Syn CAT# 610787, anti-GSK-3b CAT#
612313 and anti-pGSK-3b [purified mouse anti-GSK-3B (pY216)
CAT# 612313], from BD Transduction Labs [San Jose, CA];
anti-b-actin SC-1616 from Santa Cruz Biotechnology, Inc. [Santa
Cruz, CA]; the CP-13 and PHF-1 antibodies [recognizing Tau-
Ser202 and Tau-Ser396/404, respectively] were gifts from Dr.
Peter Davies [New York]; anti-Proteasome 19S Subunit S6’
CAT# AP-111 and anti-Proteasome 20S Subunit a5 CAT# AP-
120, from BostonBiochem [Cambridge, MA]; anti-Atg12
(D88H11) CAT# 4180, anti-Atg7 CAT# 2631, anti-LC3B
(D11) XP CAT# 3868, anti-mTOR (7C10) CAT# 2983, anti-
Hsp70 CAT# 4872, anti-Hsp90b CAT# 5087, from Cell
Signaling Technology, Inc. [Danvers, MA]; anti-Beclin 1 CAT#
NBP1-45382 from Novus Biologicals, LLC [Littleton, CO]; anti-
beta Synuclein CAT# ab25650 and anti-Hsc70 [N27F34] CAT#
ab90347 from Abcam PLC [Cambridge, MA]; and anti-a-
Tubulin CAT# T6074 and anti-Acetylated-Tubulin CAT#
T7451 from Sigma-Aldrich, Co. [St. Louis, MO].
Human striata
Postmortem striatal tissue from PD and age-matched non-
diseased controls were obtained and processed as described
previously [25].
Animals
Mice used in these studies were 2–3 month old males with a
mixed C57BL/66129S background. All studies with animals were
conducted under strict guidelines of the National Institutes of
Health and were approved by Georgetown University Animal
Care and Use Committee.
Treatment of mice with maneb and paraquat
Mice were injected essentially as described previously [10,11].
Male mice on a mixed C57BL/66129S background received
intraperitoneal injections of 10 mg/kg paraquat (PQ) and/or
30 mg/kg maneb (MB) in sterile filtered 0.9% saline. Control mice
were injected with saline alone (vehicle treated). Since PQ and MB
were administered as separate injections, two separate injections of
saline were administered to control mice, and a single injection of
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that all animals received the same number of injections and the
same total volume of injected saline (adjusted for weight). Toxin
injections were administered first, followed by saline injections.
Treatment was administered twice weekly for six weeks (12 total
injections) following which all animals were sacrificed. Striata were
dissected for Western blot analysis.
Determination of 26S proteasome activity
Striatal tissues were re-suspended in 10 vol of ice-cold extraction
buffer (10 mM Tris–HCl, pH 7.4, 1 mM EDTA, 4 mM dithio-
threitol, 20% glycerol) and disrupted by 50 strokes in a dounce
homogenizer on ice. Lysates were cleared by centrifugation
(20 minutes,16,0006g, 4uC). Soluble protein concentration was
determined by Bio-Rad Protein Assay (Bio-Rad, Hercules, CA),
and protein concentrations were equalized to 0.75 mg/ml by
dilution in extraction buffer. For determination of 26S proteasome
activity, 10 ml of lysate was combined with 85 ml of reaction buffer
(20 mM Tris–HCl pH 7.4, 1 mM ATP, 20% glycerol) plus 5 mlo f
0.1 mg/ml N-Succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcou-
marin (suc-LLVY-AMC; Biomol, Plymouth Meeting, PA),and
incubated at 37uC for 60 minutes. Reactions including 50 mM
clasto-lactacystin b-lactone (lactacystin) 26S proteasome inhibitor
were conducted in parallel. After incubation, reactions were
transferred to opaque 96-well plates, and AMC fluorescence was
measured on a Victor3V, 1420 Multi-label Counter (PerkinElmer,
Waltham, MA) for 1 second, using an excitation filter of 355 nm
and an emission filter of 460 nm. Lactacystin-resistant activity was
subtracted from total activity to determine 26S activity.
Preparation of lysates for Western blots
Tissues were homogenized in buffer containing 10 mM Tris-
HCl, pH 7.4,1 M NaCl, 250 mM sucrose, 5 mM KCl, 2 mM
CaCl2, 1 mM MgCl2, 1 mM dithiothreitol, 1 mM EDTA, 1 mM
EGTA, 10 mg/ml each of phosphatase inhibitor cocktail (Halt
Phosphatase inhibitor Cocktail; Thermo Scientific, Rockford, IL)
and protease inhibitor cocktail tablets (Complete Mini, EDTA-
free; Roche Diagnostics, Mannheim, Germany). Sodium cholate
(20% in water, wt/vol) was added to a final concentration of 1%
(vol/vol). The mixture was left on ice for 30 min with brief
vortexing every 5 min, followed by centrifugation for 20 min at
16,0006 g at 4uC. The clear supernatant representing cholate-
soluble fractions, and pellets representing the cholate-insoluble
fractions, were collected. Pellet fractions were briefly sonicated
with a Branson Sonifier 250 and protein concentrations were
measured using the Lowry assay. Samples were diluted to equal
protein concentrations with homogenizing buffer, then further
diluted 1:4 with dilution buffer (50 mM Tris-HCl, pH 7.4, 5 mM
KCl, 2 mM CaCl2, 1 mM MgCl2, 1 mM EDTA, 1 mM EGTA),
so that final sodium cholate concentration was reduced to 0.2%.
Samples were then mixed with Laemmli buffer [1:1 vol/vol] and
analyzed by Western blots.
Isolation of cytoskeleton-free and cytoskeleton-
associated fractions
Tissues were extracted and separated into cytoskeleton-free and
cytoskeleton-associated fractions as described previously [22].
Briefly, tissues were homogenized in buffer [pre-warmed to room
temperature] containing 80 mM PIPES (pH 6.8), 1 mM MgCl2,
2 mM EGTA, 0.1 mM EDTA, 0.1% Triton X-100 and 30%
glycerol. Lysates were incubated at 37uC for 10 minutes prior to
centrifugation at room temperature at 14,0006g for 20 min. The
supernatant contained cytoskeleton-free fractions. The pellet,
containing cytoskeleton-associated fraction, was re-suspended in
2% SDS, 5 mM EDTA, 5 mM EGTA, 10% glycerol, 0.25 M
Tris-HCl (pH 6.8), incubated at room temperature on an inverter
for 60 min, and sonicated 3630 secs at room temperature with a
Branson Sonifier 250.
Western Blot Analysis
Western blot analysis was performed as described previously
[26,27]. Briefly, samples were analyzed on 10–20% Tris-HCl
Criterion gels (Bio-Rad), after blocking with 20 mM Tris-buffered
saline, pH 7.6 containing 0.1% Tween 20 (TBST) and 5% (wt/
vol) blotting grade blocker non-fat dry milk (Bio-Rad) for 1 hour at
room temperature. Western blots were probed with an array of
primary antibodies diluted into TBST with 5% milk at
experimentally determined concentrations ranging from 1:500 to
1:1000. After incubation for 2 hours at room temperature with
HRP-conjugated secondary antibodies (1:3000; Santa Cruz),
proteins were revealed by enhanced chemiluminescence (Perkin
Elmer). Images were scanned by Scanner EPSON Perfection
V700 Photo and then quantified using ImageJ. Proteins were
normalized to b-actin (1:1000), used as loading control.
Immunohistochemistry
IHC analysis of mouse brain coronal sections was performed as
previously described [26,27], with slight modifications. Briefly,
brains from 2–3 month old saline treated and age-matched
paraquat treated (10 mg/kg) mice were embedded in OTC and
flash frozen in isopentane. 10 mm sections fixed to super-frost
slides were washed, permeabilized, and stained in the following
manner. Each slide was washed 3 times in 1 mg/mL NaBH4,1 6
PBS pH 7.4, for 5 min at room temperature followed by washing
66, for 10 min in 16PBS pH 7.4, 1% Triton X-100, followed by
blocking in the antibody specific blocking buffer for 1 h at room
temperature in 16 PBS pH 7.4, 1% Triton X-100, 10% FCS.
Incubation with primary antibody occurred at 4uC, overnight in
the dark, in the appropriate blocking buffer using the following
concentrations for sequential staining: mouse-anti-a-Syn, 1:750;
rabbit-anti-pSer396 Tau (pTau), 1:500; rabbit-anti-mTOR, 1:500.
Following primary staining, each slice was washed 36in 16PBS
pH 7.4, 1% Triton X-100 at room temperature, incubated for
30 min in blocking buffer with the appropriate Alexafluor 488 or
594 conjugated secondary antibody, and washed 56 in 16 PBS
pH 7.4, 1% Triton X-100. Slides were mounted using Fluor-
omount-DAPI. Fluorescence images were captured using a laser
scanning confocal microscope (Olympus FV300). Paired images
between tissue from saline and paraquat treated animals for all
figures were collected at the same laser power, gain, and offset
settings. Post-collection processing with ImageJ, as well as contrast
and color adjustment was applied uniformly to all paired images.
Statistical Analysis
Results were expressed as mean 6 SEM and statistically
analyzed by the Student’s t-test between two groups. Statistical
significance was accepted at the [p,0.05] level.
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